Chandra Bhagat Pharma Limited (BOM:542934)
India · Delayed Price · Currency is INR 49.90
-2.60 (-4.95%)
At close: Aug 14, 2026
Chandra Bhagat Pharma Balance Sheet
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Assets
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Equivalents | 31.11 | 6.65 | 49.64 | 64.4 | 56.81 |
Short-Term Investments | 16.69 | 1.37 | 1.32 | 1.1 | 2.21 |
Cash & Short-Term Investments | 47.79 | 8.02 | 50.97 | 65.49 | 59.03 |
Cash Growth | 495.91% | -84.26% | -22.18% | 10.96% | 109.23% |
Accounts Receivable | 546.17 | 359.46 | 394.47 | 81.86 | 150.04 |
Other Receivables | 0.21 | 2.29 | 2.62 | 0.95 | 0.71 |
Receivables | 550.78 | 363.97 | 533.84 | 129.66 | 192.54 |
Inventory | 46.72 | 6.92 | 86.77 | 290.77 | 341.57 |
Prepaid Expenses | 0.39 | - | 1.08 | 0.3 | 0.07 |
Other Current Assets | 231.02 | 567.6 | 306.54 | 94.67 | 114.06 |
Total Current Assets | 876.7 | 946.5 | 979.18 | 580.9 | 707.26 |
Property, Plant & Equipment | 26.24 | 26.22 | 25.22 | 7.28 | 4.73 |
Long-Term Deferred Tax Assets | 1.73 | 0.69 | 0.21 | - | - |
Long-Term Deferred Charges | 2.18 | 4.37 | 6.55 | 9.59 | 12.63 |
Other Long-Term Assets | 35.21 | 37.52 | 6.89 | 8.07 | - |
Total Assets | 942.06 | 1,015 | 1,018 | 605.83 | 724.62 |
Liabilities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Accounts Payable | 318.85 | 89.53 | 132.31 | 31.02 | 26.72 |
Accrued Expenses | 2.97 | 1.94 | 2.24 | 9.02 | 10.42 |
Short-Term Debt | 134.01 | 180.52 | 140.58 | 137.39 | 143.85 |
Current Portion of Long-Term Debt | 5.38 | 5.25 | 9.56 | 12.78 | 13.12 |
Current Income Taxes Payable | 11.62 | 4.01 | 6.03 | 2.93 | 2.71 |
Other Current Liabilities | 111.99 | 411.25 | 419.87 | 76.33 | 183.7 |
Total Current Liabilities | 584.82 | 692.49 | 710.6 | 269.48 | 380.52 |
Long-Term Debt | 25.68 | 22.84 | 14.13 | 39.28 | 54.2 |
Long-Term Deferred Tax Liabilities | - | - | - | 0.14 | 0.12 |
Other Long-Term Liabilities | 0.29 | 0.29 | 3.23 | 22.16 | 23.03 |
Total Liabilities | 610.79 | 715.61 | 727.96 | 331.05 | 457.87 |
Shareholders' Equity
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Common Stock | 75.45 | 75.45 | 75.45 | 75.45 | 75.45 |
Additional Paid-In Capital | 133.71 | 133.71 | 133.71 | - | 133.71 |
Retained Earnings | 122.1 | 90.53 | 80.93 | - | 57.6 |
Comprehensive Income & Other | - | - | - | 199.34 | -0 |
Shareholders' Equity | 331.27 | 299.69 | 290.09 | 274.79 | 266.76 |
Total Liabilities & Equity | 942.06 | 1,015 | 1,018 | 605.83 | 724.62 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Total Debt | 165.07 | 208.6 | 164.27 | 189.45 | 211.18 |
Net Cash (Debt) | -117.28 | -200.58 | -113.3 | -123.95 | -152.15 |
Net Cash Growth | - | - | - | - | - |
Net Cash Per Share | -15.54 | -26.58 | -15.02 | -16.43 | -20.17 |
Filing Date Shares Outstanding | 7.55 | 7.55 | 7.55 | 7.55 | 7.55 |
Total Common Shares Outstanding | 7.55 | 7.55 | 7.55 | 7.55 | 7.55 |
Working Capital | 291.87 | 254.02 | 268.58 | 311.42 | 326.75 |
Book Value Per Share | 43.90 | 39.72 | 38.45 | 36.42 | 35.35 |
Tangible Book Value | 331.27 | 299.69 | 290.09 | 274.79 | 266.76 |
Tangible Book Value Per Share | 43.90 | 39.72 | 38.45 | 36.42 | 35.35 |
Land | 2.74 | 2.74 | 2.74 | 2.74 | 2.74 |
Machinery | 45.17 | 35.96 | 31.24 | 8.42 | 4.76 |